1.1. Most Frequent Symptoms Among 3,558 Registry Participants

3.1. Factors Leading to Individual Differences in Response to PB
3.2. Reasons Extrapolation from Myasthenia to Normals May Not Be Valid
3.3. Aging Half-Time of Nerve Agents
3.4. Percentage of Population Within Target Area Exposed to Various Levels of Nerve Agent
3.5. Effect of Therapy With and Without Pyridostigmine Pretreatment on Protective Ratios (PR) in Animals Exposed to Nerve Agents
3.6. PB PRs for Soman Exposure (Guinea Pigs)
3.7. Problems Leading to Medical Attention After PB Use in the PGW
3.8. Symptom Frequency: Cross-Sectional Survey of 213 Israeli Soldiers

5.1. Most Frequent Principal Diagnoses in PGW Registry Personnel
5.2. Symptom Prevalence as Primary and Any Diagnosis
5.3. Symptom Prevalence in Those with a Primary Diagnosis of Good Health
5.4. Symptom Prevalence in Those Given a Diagnosis Other Than SSID
5.5. Symptom Prevalence in Those Diagnosed with SSID
5.6. Registry Participation Predictors
5.7. Odds Ratios for CDC-Defined Persian Gulf War Illness, in Veterans from the PGW, Bosnia, or Gulf-Era Veterans Not Deployed to the Gulf

8.1. Effects of Different Esterases on PB Inactivation
8.2. Individual Variation in Esterases in Humans
8.3. PON Isoforms: Substrate Activities in Human Sera for Sarin, Soman, and PON

9.1. Sites of Action of PB: Possible Sites at Which Interaction May Occur with Other Drugs and Chemicals
9.2. Data Matrix: Binary Interactions Between PB and Selected Exposures

10.1. Bromide Blood Concentration and Toxicity

11.1. Complaints of PGW Veterans Enrolled in Persian Gulf Health Registry
11.2. Symptoms in MCS Patients
11.3. New Onset Intolerances Reported by Gulf War Veterans

A.1. Pyridostigmine Pharmacokinetic Data
A.2. Animal Data

B.1. Physiological Findings
B.2. Performance
B.3. Side Effects